Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30119% above fair value
$43.65+0.41 (+0.95%)
Close on Nov 12, 2026Market cap $50.87BP/E 72.8Yield –
Teva Pharmaceutical Industries total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Teva Pharmaceutical Industries's total debt was $4.50B at Jun 30, 2026. For fiscal 2025 it was $1.82B, up 2.2% from the year before. Over ten years it grew 1.4% a year on average. The highest annual figure on record is $4.28B in fiscal 2011.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.82B | +2.2% |
| FY2024 | Dec 31, 2024 | $1.78B | +6.5% |
| FY2023 | Dec 31, 2023 | $1.67B | -20.7% |
| FY2022 | Dec 31, 2022 | $2.11B | +47.9% |
| FY2021 | Dec 31, 2021 | $1.43B | -55.3% |
| FY2020 | Dec 31, 2020 | $3.19B | +35.9% |
| FY2019 | Dec 31, 2019 | $2.35B | +5.8% |
| FY2018 | Dec 31, 2018 | $2.22B | -39.2% |
| FY2017 | Dec 31, 2017 | $3.65B | +11.3% |
| FY2016 | Dec 31, 2016 | $3.28B | +106.7% |
| FY2015 | Dec 31, 2015 | $1.59B | -10.0% |
| FY2014 | Dec 31, 2014 | $1.76B | -2.4% |
| FY2013 | Dec 31, 2013 | $1.80B | -40.0% |
| FY2012 | Dec 31, 2012 | $3.01B | -29.8% |
| FY2011 | Dec 31, 2011 | $4.28B | +198.9% |
| FY2010 | Dec 31, 2010 | $1.43B | +117.3% |
| FY2009 | Dec 31, 2009 | $659.00M | -77.3% |
| FY2008 | Dec 31, 2008 | $2.91B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.50B | +869.8% |
| Q1 FY2026 | Mar 31, 2026 | $2.61B | +520.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.82B | +2.2% |
| Q3 FY2025 | Sep 30, 2025 | $24.00M | -99.1% |
| Q2 FY2025 | Jun 30, 2025 | $464.00M | -77.8% |
| Q1 FY2025 | Mar 31, 2025 | $421.00M | -86.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.78B | +6.5% |
| Q3 FY2024 | Sep 30, 2024 | $2.58B | +74.4% |
| Q2 FY2024 | Jun 30, 2024 | $2.09B | +5.8% |
| Q1 FY2024 | Mar 31, 2024 | $3.06B | +199.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.67B | -20.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.48B | -46.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.98B | +15.2% |
| Q1 FY2023 | Mar 31, 2023 | $1.02B | -50.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.11B | +47.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.77B | +2.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.72B | -51.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.08B | -23.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.43B | -55.3% |
| Q3 FY2021 | Sep 30, 2021 | $2.71B | +28.6% |
| Q2 FY2021 | Jun 30, 2021 | $3.53B | +114.1% |
| Q1 FY2021 | Mar 31, 2021 | $2.70B | +65.5% |
| Q4 FY2020 | Dec 31, 2020 | $3.19B | +35.9% |
| Q3 FY2020 | Sep 30, 2020 | $2.11B | -32.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.65B | -40.5% |
| Q1 FY2020 | Mar 31, 2020 | $1.63B | -41.6% |
| Q4 FY2019 | Dec 31, 2019 | $2.35B | +5.8% |
| Q3 FY2019 | Sep 30, 2019 | $3.13B | +17.1% |
| Q2 FY2019 | Jun 30, 2019 | $2.77B | +117.8% |
| Q1 FY2019 | Mar 31, 2019 | $2.79B | +114.3% |
| Q4 FY2018 | Dec 31, 2018 | $2.22B | -39.2% |
| Q3 FY2018 | Sep 30, 2018 | $2.67B | -2.1% |
| Q2 FY2018 | Jun 30, 2018 | $1.27B | +2.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.30B | -33.0% |
| Q4 FY2017 | Dec 31, 2017 | $3.65B | +11.3% |
| Q3 FY2017 | Sep 30, 2017 | $2.73B | -25.7% |
| Q2 FY2017 | Jun 30, 2017 | $1.25B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.94B | – |
| Q4 FY2016 | Dec 31, 2016 | $3.28B | – |
| Q3 FY2016 | Sep 30, 2016 | $3.68B | – |
See a number that looks wrong?